TABLE OF CONTENTS XXXIII Tuberculosis ................................................................................................................... 829 Nontuberculous Mycobacteria (Environmental Mycobacteria, Mycobacteria Other Than Mycobacterium tuberculosis)............................................................. 853 Tularemia ...................................................................................................................... 861 Endemic Typhus (Murine Typhus) ................................................................................ 864 Epidemic Typhus (Louseborne or Sylvatic Typhus) ...................................................... 865 Ureaplasma urealyticum and Ureaplasma parvum Infections .................................................. 867 Varicella-Zoster Virus Infections ................................................................................... 869 Vibrio Infections .............................................................................................................. 883 Cholera (Vibrio cholerae) ............................................................................................. 883 Other Vibrio Infections .............................................................................................. 887 West Nile Virus .............................................................................................................. 888 Yersinia enterocolitica and Yersinia pseudotuberculosis Infections (Enteritis and Other Illnesses) ............................................................................................... 891 Zika Virus ...................................................................................................................... 894 SECTION 4 ANTIMICROBIAL AGENTS AND RELATED THERAPY Introduction ................................................................................................................... 903 Fluoroquinolones ...................................................................................................... 904 Tetracyclines ............................................................................................................ 905 Other Agents ............................................................................................................ 906 Antimicrobial Resistance and Antimicrobial Stewardship: Appropriate and Judicious Use of Antimicrobial Agents ........................................................... 906 Antimicrobial Resistance .......................................................................................... 906 Factors Contributing to Resistance .......................................................................... 907 Antimicrobial Resistance Threats ............................................................................ 907 Actions to Prevent or Slow Antimicrobial Resistance .............................................. 908 Antimicrobial Stewardship ....................................................................................... 909 Role of the Medical Provider ................................................................................... 910 Principles of Appropriate Use of Antimicrobial Therapy for Upper Respiratory Tract Infections .................................................................... 910 Drug Interactions ........................................................................................................... 913 Tables of Antibacterial Drug Dosages ........................................................................... 914 Sexually Transmitted Infections .................................................................................... 933 Antifungal Drugs for Systemic Fungal Infections .......................................................... 938 Polyenes .................................................................................................................. 938 Pyrimidines ............................................................................................................... 940 Azoles ....................................................................................................................... 940 Echinocandins .......................................................................................................... 941 Recommended Doses of Parenteral and Oral Antifungal Drugs ................................... 945 Topical Drugs for Superficial Fungal Infections ............................................................ 956 Non-HIV Antiviral Drugs .............................................................................................. 966 Drugs for Parasitic Infections ......................................................................................... 985 MedWatch—The FDA Safety Information and Adverse Event-Reporting Program ........................................................................... 1026
Previous Page Next Page